Sign In
Last checked at 
9 Sep 2024 07:00
ValiRx plc
("ValiRx" or the "Company")
Investor Evening - Tuesday 24 September 2024
London, UK - ValiRx Plc is pleased to welcome current shareholders and interested investors to a ValiRx Plc Investor Evening organised by Shard Capital Partners LLP on Tuesday, 24 September 2024.
At the event, a presentation will be delivered by Dr Mark Eccleston, Chief Executive of the Company, followed by a Q&A session. Drinks will be provided.
The event will take place at 25 Eccleston Place London SW1W 9NF, LondonĀ and will start at 5.30pm (UK).
To gain admission, please RSVP by completing the attendance form via the following link: https://corporate-update-from-fusion-antibodies-plc-and-valirx-plc-tick.eventbrite.co.uk
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 (0) 115 784 0026 www.valirx.com info@valirx.com |
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director Ā | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
Ā
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.Ā
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit:Ā www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Ā
Follow the stocks
